The Multicenter Study for Effects of Eplerenone on Cardiac Diastolic Dysfunction in Hypertensive Patients
- Conditions
- Hypertensive patients with cardiac diastolic dysfunction and preserved ejection fraction
- Registration Number
- JPRN-UMIN000006415
- Lead Sponsor
- Graduate School of Medical Sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 180
Not provided
1.Patients with severe renal failure (Ccr<=50ml/mi. Kakuta Y et al. Clin Exp Nephrol. 2010,14(1):63-7.) 2.Serum potassium level is equal or more than 5.0 mEq/L 3.Patients with severe hepatic insufficiency (Child-Pugh Score class C) 4.Patients currently under treatment of Itraconazole, Ritonavir, or Nelfinavir. 5.Patients with hypertrophic obstructive cardiomyopathy, cardiac amyloidosis, cardiac sarcoidosis, connective tissue disease, or malignancy 6.Patients with evere valvular disease 7.Patients with secondary hypertension 8.Patients underwent operative treatment or coronary angioplasty in the past one month 9.Patients treated with eplerenone or spironolactone in the past three months 10.Women who are wising to be pregnant, or of childbearing potential 11.Patients whose physicians determined inadequate to participate the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method